drugset / Trial / NCT00927563

Tolcapone Treatment of Pathological Gambling

NCT00927563

Phase 2 Completed 24 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in pathological gambling.

Timeline

Start
2009-06
Primary completion
2012-05
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolcapone Unknown 300 mg Oral

Indications